Proficio Capital Partners LLC Boosts Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Proficio Capital Partners LLC raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 34,497.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 242,528 shares of the company’s stock after buying an additional 241,827 shares during the period. Proficio Capital Partners LLC owned 0.78% of Medpace worth $80,575,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State Street Corp increased its stake in Medpace by 7.2% in the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after buying an additional 50,312 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Medpace by 7.6% during the 3rd quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock valued at $209,885,000 after acquiring an additional 44,371 shares during the period. Wellington Management Group LLP grew its position in shares of Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after acquiring an additional 109,886 shares during the period. American Capital Management Inc. grew its position in shares of Medpace by 2.6% during the 3rd quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock valued at $127,060,000 after acquiring an additional 9,592 shares during the period. Finally, FMR LLC grew its position in shares of Medpace by 11.8% during the 3rd quarter. FMR LLC now owns 231,019 shares of the company’s stock valued at $77,114,000 after acquiring an additional 24,362 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 3.9 %

MEDP opened at $326.11 on Friday. The company has a 50 day moving average of $342.86 and a 200 day moving average of $346.05. The company has a market cap of $9.94 billion, a PE ratio of 25.82, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.